Thoroughbred Financial Services LLC Takes Position in AstraZeneca PLC $AZNCF

Thoroughbred Financial Services LLC purchased a new stake in AstraZeneca PLC (OTCMKTS:AZNCF) in the 4th quarter, HoldingsChannel reports. The fund purchased 8,475 shares of the company’s stock, valued at approximately $1,487,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Mascoma Wealth Management LLC acquired a new stake in shares of AstraZeneca in the fourth quarter valued at about $46,000. Elyxium Wealth LLC acquired a new stake in shares of AstraZeneca in the fourth quarter valued at about $102,000. Redmont Wealth Advisors LLC acquired a new stake in shares of AstraZeneca in the fourth quarter valued at about $122,000. Valley Wealth Managers Inc. acquired a new stake in shares of AstraZeneca in the fourth quarter valued at about $144,000. Finally, Cary Street Partners Investment Advisory LLC acquired a new stake in shares of AstraZeneca in the fourth quarter valued at about $412,000. Institutional investors and hedge funds own 40.87% of the company’s stock.

AstraZeneca Price Performance

Shares of AZNCF stock opened at $187.10 on Friday. AstraZeneca PLC has a 1-year low of $122.26 and a 1-year high of $195.00. The stock has a 50-day moving average of $187.10 and a 200-day moving average of $185.25.

AstraZeneca Company Profile

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.